← Back to Search

Contrast-Enhanced Ultrasound for Renal Cell Carcinoma

N/A
Waitlist Available
Led By Anil Kapoor, MD, FRCSC
Research Sponsored by St. Joseph's Healthcare Hamilton
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
at least 18 years of age and capable of giving informed consent
patient undergoing CT of MRI for monitoring of renal lesions after radiofrequency ablation
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 months post radiofrequency ablation
Awards & highlights

Study Summary

This trial is investigating whether contrast-enhanced ultrasound (CEUS) can be an effective tool for follow-up monitoring of kidney cancer patients who have undergone radiofrequency ablation (RFA), by comparing the results of their standard follow-up CT scans (or MRIs if applicable) with the results of CEUS.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 months post radiofrequency ablation
This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 months post radiofrequency ablation for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Cognitive Therapy
Secondary outcome measures
Quality of life data

Trial Design

1Treatment groups
Experimental Treatment
Group I: Contrast-Enhanced UltrasoundExperimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

St. Joseph's Healthcare HamiltonLead Sponsor
195 Previous Clinical Trials
25,394 Total Patients Enrolled
McMaster UniversityOTHER
877 Previous Clinical Trials
2,596,030 Total Patients Enrolled
Anil Kapoor, MD, FRCSCPrincipal InvestigatorMcMaster University
3 Previous Clinical Trials
240 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~3 spots leftby Mar 2025